Rishabh Jain, Medical Consultant at Renova Hospital (RHL), shared on X:
“Progression on immunotherapy doesn’t always mean immunotherapy has failed!
In metastatic NSCLC, what if we could ablate a few progressing lesions and continue the same immunotherapy?
A new systematic review and meta-analysis explores local ablative treatment for oligoprogression.
The key question: Can we control resistant clones locally while preserving systemic benefit?
Promising strategy, but patient selection and prospective validation remain crucial.”
Title: Local ablative treatment for oligoprogression during immunotherapy in metastatic non-small-cell lung cancer: a systematic review and meta-analysis
Authors: Ismaell Massalha, Adham Hijab, Reem Zabit, Jamal Zidan, Ory Wiesel, Nir Peled
You can also read:
